Description:
This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to
evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This
study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with
HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard
therapy or for which no standard therapy exists, particularly urothelial cancer, biliary
tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.
Title
- Brief Title: A Study of TAS0728 in Patients With Solid Tumors With HER2 or HER3 Abnormalities
- Official Title: A Phase 1/2, Open Label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of TAS0728, an Oral Covalent Binding Inhibitor of HER2, in Subjects With Advanced Solid Tumors With HER2 or HER3 Abnormalities
Clinical Trial IDs
- ORG STUDY ID:
TO-TAS0728-101
- SECONDARY ID:
2017-004415-39
- NCT ID:
NCT03410927
Conditions
- Advanced Solid Tumors
- HER2 Abnormalities
- HER3 Abnormalities
Interventions
Drug | Synonyms | Arms |
---|
TAS0728 | | TAS0728 |
Purpose
This is a First-in-Human (FIH), 2-part, Phase 1/2, open-label, multicenter study design to
evaluate the safety, tolerability, PK, pharmacodynamics, PGx, and efficacy of TAS0728. This
study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors with
HER2 or HER3 overexpression, amplification, or mutation who have progressed despite standard
therapy or for which no standard therapy exists, particularly urothelial cancer, biliary
tract cancer, metastatic breast cancer, non-small cell lung cancer and colorectal cancer.
Trial Arms
Name | Type | Description | Interventions |
---|
TAS0728 | Experimental | Group 1: Urothelial cancer with HER2 or HER3 mutation Group 2: Biliary tract cancer with HER2 or HER3 mutation Group 3: Breast cancer with HER2 or HER3 mutation Group 4: Breast cancer with HER2 amplification or overexpression as per American Society of Clinical Oncology - College of American Pathologists (ASCO-CAP) 2013 guidelines Group 5: Non-small cell lung cancer (NSCLC) with HER2 or HER3 mutation Group 6: Colorectal cancer (CRC) with HER2 mutation or amplification Group 7: Other tumors with HER2 or HER3 mutation, amplification, or overexpression (eg, gastric or gastroesophageal junction (GEJ), endometrial) | |
Eligibility Criteria
Inclusion Criteria:
1. Male or females with an age ≥ 18 years.
2. Subjects with histological- or cytological-confirmed, advanced cancer, who have
progressed on (or not been able to tolerate) standard therapy or for whom no standard
anticancer therapy exists
1. For Phase 1, only subjects HER2 or HER3 molecular/genetic alterations will be
enrolled.
2. For Phase 2a, subjects with one of the following tumor types will be enrolled:
i. Urothelial cancer with HER2 or HER3 mutation ii. Biliary tract cancer with HER2 or
HER3 mutation iii. Breast cancer with HER2 or HER3 mutation iv. Breast cancer with
HER2 amplification or overexpression v. NSCLC with HER2 or HER3 mutation vi. CRC with
HER2 mutation or amplification vii. Other tumors with HER2
mutation/amplification/overexpression or HER3 mutation (gastric/GEJ, endometrial).
3. At least 1 measurable lesion for solid tumor
4. Is able to take medications orally (e.g., no feeding tube).
5. Able to agree to and sign informed consent and to comply with the protocol
6. Has adequate organ function
Exclusion Criteria:
1. Has a serious illness or medical condition(s)
2. Has received treatment with any proscribed treatments within specified time frames
prior to study drug administration
3. Impaired cardiac function or clinically significant cardiac disease
Maximum Eligible Age: | N/A |
Minimum Eligible Age: | 18 Years |
Eligible Gender: | All |
Healthy Volunteers: | No |
Primary Outcome Measures
Measure: | Number of patients experiencing Dose Limiting Toxicity graded according to CTCAE Version 4.03, observed in the Cycle 1 in order to meet the objective of assessment of the MTD of TAS0728. |
Time Frame: | 21-day cycles |
Safety Issue: | |
Description: | |
Secondary Outcome Measures
Measure: | Maximum Plasma Concentration (Cmax) after administration of TAS0728 (Phase 1) |
Time Frame: | 21 days in Cycle 1 |
Safety Issue: | |
Description: | |
Measure: | Area under the plasma drug concentration-time curve (AUC) after administration of TAS0728 (Phase 1) |
Time Frame: | 21 days in Cycle 1 |
Safety Issue: | |
Description: | |
Measure: | Disease Control Rate using RECIST 1.1 (phase 1 and 2) |
Time Frame: | 3 years |
Safety Issue: | |
Description: | |
Measure: | Progression free survival (phase 1 and 2) |
Time Frame: | 3 years |
Safety Issue: | |
Description: | |
Measure: | Duration of response (phase 1 and 2) |
Time Frame: | 3 years |
Safety Issue: | |
Description: | |
Measure: | Overall survival (phase 1 and 2) |
Time Frame: | 3 years |
Safety Issue: | |
Description: | |
Details
Phase: | Phase 1/Phase 2 |
Primary Purpose: | Interventional |
Overall Status: | Active, not recruiting |
Lead Sponsor: | Taiho Oncology, Inc. |
Trial Keywords
- Phase I
- solid tumors
- pharmacokinetics
- pharmacodynamics
- MTD
- TAS0728
- HER2
- HER3 mutation
- amplification or overexpression
- Urothelial cancer with HER2 or HER3 mutation
- Biliary tract cancer with HER2 or HER3 mutation
- MBC with HER2 amplification or overexpression or HER3 mutation
- NSCLC with HER2 or HER3 mutation
- CRC with HER2 or HER3 mutation
- amplification
Last Updated
August 14, 2020